{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:35Z","timestamp":1786119575389,"version":"build-2736575974"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/gme.0b013e3181fcabaa","type":"journal-article","created":{"date-parts":[[2011,1,15]],"date-time":"2011-01-15T01:10:49Z","timestamp":1295053849000},"page":"575-581","source":"Crossref","is-referenced-by-count":1,"title":["Involvement of G-463A MPO gene polymorphism in the response of postmenopausal women to hormone therapy"],"prefix":"10.1097","volume":"18","author":[{"given":"Ainhoa","family":"Ruiz del Agua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Aurrekoetxea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Elorriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Gu\u00e9raud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Bego\u00f1a","family":"Ruiz-Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ignacio","family":"Ruiz-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210211","first-page":"1307","article-title":"Factors affecting the progression of atherosclerosis in the coronary arteries.","volume":"65","author":"Morka","year":"2007","journal-title":"Kardiol Pol"},{"key":"R2-20-20210211","first-page":"381","article-title":"Atherosclerosis and oxidative stress.","volume":"23","author":"Bonomini","year":"2008","journal-title":"Histol Histopathol"},{"key":"R3-20-20210211","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1172\/JCI117342","article-title":"Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions.","volume":"94","author":"Daugherty","year":"1994","journal-title":"J Clin Invest"},{"key":"R4-20-20210211","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2143\/AC.63.2.2029520","article-title":"Plasma myeloperoxidase is related to the severity of coronary artery disease.","volume":"63","author":"Duzguncinar","year":"2008","journal-title":"Acta Cardiol"},{"key":"R5-20-20210211","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11883-007-0027-2","article-title":"The role of myeloperoxidase in HDL oxidation and atherogenesis.","volume":"9","author":"Heinecke","year":"2007","journal-title":"Curr Atheroscler Rep"},{"key":"R6-20-20210211","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000041062","article-title":"Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?","volume":"104","author":"Kutter","year":"2000","journal-title":"Acta Haematol"},{"key":"R7-20-20210211","doi-asserted-by":"crossref","first-page":"14412","DOI":"10.1074\/jbc.271.24.14412","article-title":"An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element.","volume":"271","author":"Piedrafita","year":"1996","journal-title":"J Biol Chem"},{"key":"R8-20-20210211","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V90.7.2730","article-title":"An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia.","volume":"90","author":"Reynolds","year":"1997","journal-title":"Blood"},{"key":"R9-20-20210211","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1067\/mhj.2001.116769","article-title":"A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians.","volume":"142","author":"Nikpoor","year":"2001","journal-title":"Am Heart J"},{"key":"R11-20-20210211","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1196\/annals.1365.034","article-title":"The cardiovascular effects of selective estrogen receptor modulators.","volume":"1092","author":"Christodoulakos","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"R12-20-20210211","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.287.7.847","article-title":"Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.","volume":"287","author":"Barrett-Connor","year":"2002","journal-title":"JAMA"},{"key":"R13-20-20210211","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/13697130600963272","article-title":"Lessons from RUTH.","volume":"9","author":"Pines","year":"2006","journal-title":"Climacteric"},{"key":"R14-20-20210211","first-page":"554","article-title":"Understanding the controversy about hormonal replacement therapy: insights from estrogen effects on experimental and clinical atherosclerosis.","volume":"100","author":"Arnal","year":"2007","journal-title":"Arch Mal Coeur Vaiss"},{"key":"R15-20-20210211","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJM199304153281501","article-title":"Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.","volume":"328","author":"Nabulsi","year":"1993","journal-title":"N Engl J Med"},{"key":"R16-20-20210211","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM199109123251102","article-title":"Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study.","volume":"325","author":"Stampfer","year":"1991","journal-title":"N Engl J Med"},{"key":"R17-20-20210211","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0008-6363(01)00466-7","article-title":"Estrogen replacement therapy, atherosclerosis, and vascular function.","volume":"53","author":"Mikkola","year":"2002","journal-title":"Cardiovasc Res"},{"key":"R18-20-20210211","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R19-20-20210211","doi-asserted-by":"crossref","first-page":"933","DOI":"10.7326\/0003-4819-133-12-200012190-00008","article-title":"A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.","volume":"133","author":"Grodstein","year":"2000","journal-title":"Ann Intern Med"},{"key":"R20-20-20210211","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.288.1.49","article-title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/Progestin Replacement Study follow-up (HERS II).","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA"},{"key":"R21-20-20210211","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0378-5122(02)00139-1","article-title":"National differences in lipid response to postmenopausal hormone replacement therapy.","volume":"42","author":"Ranta","year":"2002","journal-title":"Maturitas"},{"key":"R22-20-20210211","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2006-03-013151","article-title":"Effect of genetic variations in platelet glycoproteins Ib and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy.","volume":"109","author":"Bray","year":"2007","journal-title":"Blood"},{"key":"R23-20-20210211","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.maturitas.2007.01.008","article-title":"No effect of menstrual cycle on LDL oxidizability and particle size.","volume":"57","author":"Ruiz-Sanz","year":"2007","journal-title":"Maturitas"},{"key":"R24-20-20210211","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.fertnstert.2009.05.028","article-title":"Serum oxidizability and antioxidant status in patients undergoing in vitro fertilization.","volume":"94","author":"Aurrekoetxea","year":"2010","journal-title":"Fertil Steril"},{"key":"R25-20-20210211","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.freeradbiomed.2005.08.011","article-title":"Enzyme immunoassay for a urinary metabolite of 4-hydroxynonenal as a marker of lipid peroxidation.","volume":"40","author":"Gueraud","year":"2006","journal-title":"Free Radic Biol Med"},{"key":"R26-20-20210211","first-page":"602","article-title":"No substantial difference in genotype frequencies of interleukin and myeloperoxidase polymorphisms between malignant lymphoma patients and non-cancer controls.","volume":"86","author":"Matsuo","year":"2001","journal-title":"Haematologica"},{"key":"R27-20-20210211","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/oxfordjournals.jhered.a111573","article-title":"Genepop (version-1.2)-population-genetics software for exact tests and ecumenicism.","volume":"86","author":"Raymond","year":"1995","journal-title":"J Hered"},{"key":"R28-20-20210211","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clinbiochem.2008.01.017","article-title":"The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes.","volume":"41","author":"Makela","year":"2008","journal-title":"Clin Biochem"},{"key":"R29-20-20210211","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1047-2797(00)00189-7","article-title":"Correlates of serum - and -tocopherol in the Women's Health Initiative.","volume":"11","author":"White","year":"2001","journal-title":"Ann Epidemiol"},{"key":"R30-20-20210211","doi-asserted-by":"crossref","first-page":"1E","DOI":"10.1016\/S0002-9149(02)02402-5","article-title":"Introduction: the role of hormone replacement therapy in prevention and treatment of cardiovascular disease in postmenopausal women.","volume":"89","author":"Mishell","year":"2002","journal-title":"Am J Cardiol"},{"key":"R31-20-20210211","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0735-1097(03)00156-6","article-title":"Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women.","volume":"41","author":"Vongpatanasin","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R32-20-20210211","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/humrep\/del245","article-title":"Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.","volume":"21","author":"Ho","year":"2006","journal-title":"Hum Reprod"},{"key":"R33-20-20210211","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1538-7836.2008.02970.x","article-title":"Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers.","volume":"6","author":"Eilertsen","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R34-20-20210211","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1210\/jc.2002-021557","article-title":"Endothelial function and menopause: effects of raloxifene administration.","volume":"88","author":"Colacurci","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-20-20210211","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1365-2796.2003.01156.x","article-title":"Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women.","volume":"254","author":"Duschek","year":"2003","journal-title":"J Intern Med"},{"key":"R36-20-20210211","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/01.gme.0000172267.24949.70","article-title":"Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy.","volume":"12","author":"Vitale","year":"2005","journal-title":"Menopause"},{"key":"R37-20-20210211","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cardiores.2004.12.012","article-title":"Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen.","volume":"66","author":"Dubey","year":"2005","journal-title":"Cardiovasc Res"},{"key":"R38-20-20210211","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1126\/science.1112062","article-title":"Molecular and cellular basis of cardiovascular gender differences.","volume":"308","author":"Mendelsohn","year":"2005","journal-title":"Science"},{"key":"R39-20-20210211","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coph.2006.10.009","article-title":"Estrogens and SERMs in coronary heart disease.","volume":"7","author":"Regitz-Zagrosek","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"R40-20-20210211","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/0003319708316899","article-title":"Baseline ICAM-1 and VCAM-1 are increased in initially healthy middle-aged men who develop cardiovascular disease during 6.6 years of follow-up.","volume":"60","author":"Schmidt","year":"2009","journal-title":"Angiology"},{"key":"R41-20-20210211","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/03014460110048530","article-title":"The relationship of soluble ICAM-1, VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors in healthy men and women.","volume":"28","author":"Demerath","year":"2001","journal-title":"Ann Hum Biol"},{"key":"R42-20-20210211","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1210\/jcem.84.2.5570","article-title":"Selective estrogen receptor modulators: different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells.","volume":"84","author":"Simoncini","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R43-20-20210211","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.amjcard.2005.02.059","article-title":"Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women.","volume":"96","author":"Sumino","year":"2005","journal-title":"Am J Cardiol"},{"key":"R44-20-20210211","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1540-8175.2006.00194.x","article-title":"Relationship between plasma total antioxidant capacity and thoracic aortic intima-media thickness.","volume":"23","author":"Demirbag","year":"2006","journal-title":"Echocardiography"},{"key":"R45-20-20210211","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1536\/jhj.42.677","article-title":"Association of serum antioxidant capacity with coronary artery disease in middle-aged men.","volume":"42","author":"Nojiri","year":"2001","journal-title":"Jpn Heart J"},{"key":"R46-20-20210211","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.mrfmmm.2004.11.003","article-title":"Relationship between DNA damage, total antioxidant capacity and coronary artery disease.","volume":"570","author":"Demirbag","year":"2005","journal-title":"Mutat Res"},{"key":"R47-20-20210211","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2005.06.023","article-title":"Myeloperoxidase and its contributory role in inflammatory vascular disease.","volume":"111","author":"Lau","year":"2006","journal-title":"Pharmacol Ther"},{"key":"R48-20-20210211","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.amjmed.2003.10.025","article-title":"Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease.","volume":"116","author":"Asselbergs","year":"2004","journal-title":"Am J Med"},{"key":"R49-20-20210211","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10715769109088949","article-title":"Oestrogen-induced enhancement of myeloperoxidase activity in human polymorphonuclear leukocytes-a possible cause of oxidative stress in inflammatory cells.","volume":"14","author":"Jansson","year":"1991","journal-title":"Free Radic Res Commun"},{"key":"R50-20-20210211","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0531-5565(01)00151-6","article-title":"Plasma concentration of myeloperoxidase enzyme in pre- and post-climacterial people: related superoxide anion generation.","volume":"37","author":"Bekesi","year":"2001","journal-title":"Exp Gerontol"},{"key":"R51-20-20210211","first-page":"474","article-title":"Induced myeloperoxidase activity and related superoxide inhibition during hormone replacement therapy.","volume":"108","author":"Bekesi","year":"2001","journal-title":"BJOG"},{"key":"R52-20-20210211","first-page":"24","article-title":"Physiological concentration of 17-estradiol inhibits chemotaxis of human monocytes in response to monocyte chemotactic protein 1.","volume":"22","author":"Yamada","year":"1996","journal-title":"Artery"},{"key":"R53-20-20210211","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-5793(95)00124-R","article-title":"Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells.","volume":"360","author":"Hishikawa","year":"1995","journal-title":"FEBS Lett"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00042192-201105000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:53:57Z","timestamp":1786042437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042192-201105000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e3181fcabaa","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}